{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06363630",
            "orgStudyIdInfo": {
                "id": "CA073-1000"
            },
            "organization": {
                "fullName": "Celgene",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants",
            "officialTitle": "A Phase 1, Open-label, 2-part, 2-period, Fixed-sequence, Crossover Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics of Golcadomide (BMS-986369) in Healthy Participants",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-evaluate-the-effect-of-cytochrome-cyp-inhibitor-itraconazole-and-inducer-rifampin-on-the-drug-levels-of-golcadomide-bms-in-healthy-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08-19",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-08-19",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-09",
            "studyFirstSubmitQcDate": "2024-04-09",
            "studyFirstPostDateStruct": {
                "date": "2024-04-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-14",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Celgene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the drug-drug interaction (DDI) potential of coadministration of itraconazole or rifampin on the single dose drug levels of golcadomide."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteers"
            ],
            "keywords": [
                "pharmacokinetics",
                "BMS-986369",
                "CC-99282",
                "healthy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 36,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Itraconazole",
                        "Drug: Golcadomide"
                    ]
                },
                {
                    "label": "Part 2",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Rifampin",
                        "Drug: Golcadomide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Itraconazole",
                    "description": "Specified dose on specified days.",
                    "armGroupLabels": [
                        "Part 1"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Rifampin",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part 2"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Golcadomide",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part 1",
                        "Part 2"
                    ],
                    "otherNames": [
                        "BMS-986369"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum observed plasma concentration (Cmax)",
                    "timeFrame": "Up to Day 67"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T))",
                    "timeFrame": "Up to Day 67"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))",
                    "timeFrame": "Up to Day 67"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants with adverse events (AEs)",
                    "timeFrame": "Up to Day 69"
                },
                {
                    "measure": "Number of participants with physical exam abnormalities",
                    "timeFrame": "Up to Day 69"
                },
                {
                    "measure": "Number of participants with vital sign abnormalities",
                    "timeFrame": "Up to Day 69"
                },
                {
                    "measure": "Number of participants with clinical laboratory safety test abnormalities",
                    "timeFrame": "Up to Day 69"
                },
                {
                    "measure": "Number of participants with electrocardiogram abnormalities",
                    "timeFrame": "Up to Day 69"
                },
                {
                    "measure": "Number of participants with concomitant medications",
                    "timeFrame": "Up to Day 69"
                },
                {
                    "measure": "Number of participants with concomitant procedures",
                    "timeFrame": "Up to Day 69"
                },
                {
                    "measure": "Time of maximum observed plasma concentration (Tmax)",
                    "timeFrame": "Up to Day 67"
                },
                {
                    "measure": "Apparent terminal phase half-life (T-HALF)",
                    "timeFrame": "Up to Day 67"
                },
                {
                    "measure": "Apparent total body clearance (CLT/F)",
                    "timeFrame": "Up to Day 67"
                },
                {
                    "measure": "Apparent volume of distribution (Vz/F)",
                    "timeFrame": "Up to Day 67"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy male and female non smoking participants, of any race, as determined by the investigator to have no clinically significant deviation from normal, in medical history and physical examination which correspond to a condition that could potentially increase the risk for the participants, or jeopardize the integrity of the study data, in 12-lead ECG measurements, vital signs, and clinical laboratory determinations, at screening and at check-in.\n* Body mass index (BMI) 18.0 to 33.0 kg/m2, inclusive. BMI = weight (kg)/(height \\[m\\])2 for participants.\n* Participant is afebrile (febrile is defined as \u2265 38\u00b0C or \u2265 100.4\u00b0F), with systolic blood pressure \u2265 90 and \u2264 140 mmHg, diastolic blood pressure \u2265 50 and \u2264 90 mmHg, and pulse rate \u2265 40 and \u2264 90 beats per minute at screening, confirmed by repeat, as per clinical site's standard.\n* Must have a normal or clinically acceptable 12-lead ECG at screening: Participants must have a corrected QT interval using QTcF value \u2264 450 msec.\n* Absolute neutrophil counts must be greater than 2,500/\u03bcL at screening and Day -1.\n* Must have adequate laboratory test results for renal and hepatic function as assessed by the PI (Principal Investigator). Laboratory testing may be repeated to find all possible well-qualified participants.\n\nExclusion Criteria:\n\n* Any significant acute or chronic medical illness that presents a potential risk to the participant in the opinion of the investigator and/or may compromise the objectives of the study.\n* History of clinically significant endocrine, gastrointestinal (GI), cardiovascular (CV), peripheral vascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary (GU) abnormalities/diseases.\n* Has any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism and excretion (ADME). Appendectomy and cholecystectomy are acceptable. Prior procedures of unclear ADME significance should be reviewed with the Sponsor's Medical Monitor.\n* Other protocol-defined Inclusion/Exclusion criteria apply.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Study Connect Contact http://www.bmsstudyconnect.com/",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clinical.Trials@bms.com"
                },
                {
                    "name": "First line of the email MUST contain NCT # and Site #.",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "CenExel CNS",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30331",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kimball Johnson, Site 0002",
                            "role": "CONTACT",
                            "phone": "404-537-1281"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "ICON Lenexa",
                    "status": "RECRUITING",
                    "city": "Lenexa",
                    "state": "Kansas",
                    "zip": "66219",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Patrick Yao, Site 0001",
                            "role": "CONTACT",
                            "phone": "913-410-2674"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.95362,
                        "lon": -94.73357
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "http://www.fda.gov/MEDWATCH/safety.htm"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "CSR"
            ],
            "timeFrame": "See plan description",
            "accessCriteria": "See plan description",
            "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017964",
                    "term": "Itraconazole"
                },
                {
                    "id": "D000012293",
                    "term": "Rifampin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000935",
                    "term": "Antifungal Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000058888",
                    "term": "14-alpha Demethylase Inhibitors"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000065088",
                    "term": "Steroid Synthesis Inhibitors"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000065692",
                    "term": "Cytochrome P-450 CYP3A Inhibitors"
                },
                {
                    "id": "D000000904",
                    "term": "Antibiotics, Antitubercular"
                },
                {
                    "id": "D000000995",
                    "term": "Antitubercular Agents"
                },
                {
                    "id": "D000000900",
                    "term": "Anti-Bacterial Agents"
                },
                {
                    "id": "D000007917",
                    "term": "Leprostatic Agents"
                },
                {
                    "id": "D000019384",
                    "term": "Nucleic Acid Synthesis Inhibitors"
                },
                {
                    "id": "D000065695",
                    "term": "Cytochrome P-450 CYP2B6 Inducers"
                },
                {
                    "id": "D000065693",
                    "term": "Cytochrome P-450 Enzyme Inducers"
                },
                {
                    "id": "D000065696",
                    "term": "Cytochrome P-450 CYP2C8 Inducers"
                },
                {
                    "id": "D000065697",
                    "term": "Cytochrome P-450 CYP2C19 Inducers"
                },
                {
                    "id": "D000065698",
                    "term": "Cytochrome P-450 CYP2C9 Inducers"
                },
                {
                    "id": "D000065701",
                    "term": "Cytochrome P-450 CYP3A Inducers"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15118",
                    "name": "Rifampin",
                    "asFound": "Color",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20133",
                    "name": "Itraconazole",
                    "asFound": "Fixed dose",
                    "relevance": "HIGH"
                },
                {
                    "id": "M256158",
                    "name": "Hydroxyitraconazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M6252",
                    "name": "Clotrimazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M11796",
                    "name": "Miconazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M4254",
                    "name": "Antifungal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30564",
                    "name": "Cytochrome P-450 CYP3A Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M4311",
                    "name": "Antitubercular Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}